DURHAM, NC, December 13, 2022 (Business Wire) – Tellus Therapeutics, a neonatal care company developing treatments for newborns in the neonatal intensive care unit (NICU), announced today the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund (“PXV Fund”). The capital will be used to continue important preclinical work conducted through the seed investment with the Xontogeny development team and to advance TT-20, the company’s lead candidate for the treatment of white matter brain injury in preterm infants, as well as the company’s pipeline programs.
November 10th, 2022 (Drug Discovery News) – A mammal’s first source of nutrients comes from milk. Filled with proteins, sugars, lipids, antibodies, cells, hormones and prebiotics, milk provides the necessary nourishment to help babies develop into healthy adults (1). But scientists have discovered that milk components are not just important for child development; they can have therapeutic effects too.
Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury
DURHAM, N.C, May 12, 2021 –(BUSINESS WIRE)– Tellus Therapeutics, Inc., a biopharmaceutical company developing TT-20 as a treatment for white matter injury (WMI) and myelin repair in premature babies, today announced a seed investment from Xontogeny, LLC to advance their lead program through IND-enabling work.
Tellus Therapeutics Awarded NINDS SBIR Funding for Development of TT-20 for Treatment of Neonatal Brain Injury
DURHAM, NC, UNITED STATES, December 7, 2020 — Tellus Therapeutics today announced the award of a Phase 1 NINDS SBIR grant of $696,000 to fund further preclinical development of TT-20.
DURHAM, NORTH CAROLINA, October 21, 2020 — Tellus Therapeutics today announced that the U.S. FDA granted Orphan Drug and Rare Pediatric Drug designations for Neonatal Brain Injury Program TT-20.
DURHAM, NORTH CAROLINA, UNITED STATES, October 5, 2020 — Tellus Therapeutics today announced the appointment of Drs. Terrie Inder and Chi Hornik to the Scientific Advisory Board (SAB).
March 11th, 2020
Tellus Therapeutics is on target for a productive 2020 and is gaining traction towards its mission of developing treatments for unmet needs in newborns.
December 10, 2019
Duke Clinical & Translational Science Institute and BioLabs North Carolina have awarded the first ever Duke Golden Ticket to Dr. Eric Benner, Assistant Professor of Pediatrics in the Duke School of Medicine, and co-founder of Tellus Therapeutics.
Andy Rosen, Boston Globe Staff – October 24, 2019
A North Carolina startup that uses molecules from breast milk to help prevent cerebral palsy took home a $100,000 grant Thursday night, the top prize in the annual awards program carried out by MassChallenge, a nonprofit accelerator program for promising businesses.
SEBIO – December 4, 2018
An A-List Group Of Investors And Companies Attended The 20th Anniversary Southeast BIO Investor & Partnering Forum (SEBIO) On November 13-14th At The Loews Hotel In Atlanta.